Trinity Biotech's total inventories for the quarter that ended in Dec. 2025 was $18.83 Mil. Trinity Biotech's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was $19.48 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Trinity Biotech's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $-8.31.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Trinity Biotech's Days Inventory for the
six
months ended in Dec. 2025 was 236.70.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Trinity Biotech's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.77.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Trinity Biotech's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.77.
Trinity Biotech (NAS:TRIB) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Trinity Biotech's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Trinity Biotech's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Trinity Biotech Total Inventories Related Terms
Trinity Biotech Total Inventories Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Trinity Biotech (TRIB) has a Total Inventories of $18.83 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Trinity Biotech and its competitors.
Is Trinity Biotech's Total Inventories too high?
Trinity Biotech's current Total Inventories is $18.83 Mil. Overall, Trinity Biotech has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Total Inventories compare to PMI and NXL?
Trinity Biotech's Total Inventories of $18.83 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Trinity Biotech and its competitors. Trinity Biotech's current Total Inventories is $18.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.34 — trading 54% below its estimated fair value. The current Total Inventories is $18.83 Mil. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Total Inventories is $18.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.34 is trading 54% below its estimated GF Value™ of $0.73.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Total Inventories: $18.83 Mil
GF Value™: $0.73 vs. price of $0.34 (54% below fair value)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score
Get the complete analysis for TRIB
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
